318 related articles for article (PubMed ID: 10896846)
41. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
42. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
Struewing JP; Lerman C; Kase RG; Giambarresi TR; Tucker MA
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):169-73. PubMed ID: 7742725
[TBL] [Abstract][Full Text] [Related]
43. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
44. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
45. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study.
Brandberg Y; Arver B; Johansson H; Wickman M; Sandelin K; Liljegren A
Eur J Surg Oncol; 2012 Jan; 38(1):38-43. PubMed ID: 22032910
[TBL] [Abstract][Full Text] [Related]
46. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
47. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
[TBL] [Abstract][Full Text] [Related]
48. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
49. Bilateral prophylactic mastectomy: issues and concerns.
Stefanek ME
J Natl Cancer Inst Monogr; 1995; (17):37-42. PubMed ID: 8573451
[TBL] [Abstract][Full Text] [Related]
50. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
[TBL] [Abstract][Full Text] [Related]
51. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
[TBL] [Abstract][Full Text] [Related]
52. Screening for genetic risk of breast cancer.
Rosenthal TC; Puck SM
Am Fam Physician; 1999 Jan; 59(1):99-104, 106. PubMed ID: 9917577
[TBL] [Abstract][Full Text] [Related]
53. Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
Carpenter KM; Eisenberg S; Weltfreid S; Low CA; Beran T; Stanton AL
Health Psychol; 2014 Sep; 33(9):1003-11. PubMed ID: 23772886
[TBL] [Abstract][Full Text] [Related]
54. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.
Lerman C; Hughes C; Lemon SJ; Main D; Snyder C; Durham C; Narod S; Lynch HT
J Clin Oncol; 1998 May; 16(5):1650-4. PubMed ID: 9586874
[TBL] [Abstract][Full Text] [Related]
55. Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing.
Smith KR; West JA; Croyle RT; Botkin JR
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 2):385-92. PubMed ID: 10207644
[TBL] [Abstract][Full Text] [Related]
56. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Vasen HF; Haites NE; Evans DG; Steel CM; Møller P; Hodgson S; Eccles D; Morrison P; Stoppa Lyonet D; Chang-Claude J; Caligo M
Eur J Cancer; 1998 Nov; 34(12):1922-6. PubMed ID: 10023316
[TBL] [Abstract][Full Text] [Related]
57. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
58. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
[TBL] [Abstract][Full Text] [Related]
59. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
60. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR; Levin AM; Eisen A; Snyder C; Watson P; Cannon-Albright L; Isaacs C; Olopade O; Garber JE; Godwin AK; Daly MB; Narod SA; Neuhausen SL; Lynch HT; Weber BL
J Natl Cancer Inst; 1999 Sep; 91(17):1475-9. PubMed ID: 10469748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]